AACR 2021 – News

April 28, 2021

New transcriptional subtype of small cell lung cancer has increased sensitivity to immunotherapy

Although the new standard of treatment for the extensive disease involves the integration of platinum, etoposide and immunotherapy considering the statistical gain in survival, this benefit is limited in unselected populations, emphasizing […]
April 27, 2021

Poziotinib administered twice a day improves tolerability in NSCLC treatment with EGFR exon 20 insertion mutations

Treatment for patients with metastatic non-small cell lung cancer (mNSCLC) with EGFR or HER2 exon 20 insertion mutations represents an important unmet need   The ZENITH20-5 trial (NCT03318939), presented at the American Association for Cancer Research (AACR) […]
April 27, 2021

Avapritinib shows important efficacy in the treatment of advanced systemic mastocytosis

The potent KITD816V inhibitor induced durable responses that deepened over time in patients with this disease, regardless of prior therapy or the presented subtype  A provisional and pre-specified analysis of PATHFINDER (NCT03580655), a phase II, open-label and […]
April 26, 2021

Regular dose of osimertinib has limited activity in NSCLC with exon 20 insertion mutation

The exon 20 (ex20ins) insertion mutation is responsible for about 4 to 12% of the total EGFR gene mutations in patients with non-small cell lung cancer (NSCLC). These tumors are known to be less […]
April 26, 2021

Neoadjuvant cemiplimab for the treatment of resectable hepatocellular carcinoma demonstrates pathological complete response rates

Neoadjuvant immunotherapy can induce pathological responses and immunological memory in different malignancies, being a potential therapy for hepatocellular carcinoma   A multi-cohort, phase II study (NCT03916627) of neoadjuvant cemiplimab (an anti-PD-1 antibody) for the treatment […]
April 23, 2021

Tislelizumab, a new anti-PD-1 antibody, is an alternative for second- and third-line treatment in advanced NSCLC

RATIONALE 303 trial, presented at AACR 2021, compared the efficacy and safety of monoclonal antibody versus docetaxel   The RATIONALE 303 trial (NCT03358875), which compared the efficacy and safety of tislelizumab versus docetaxel as second- or third-line therapy for […]
April 23, 2021

EVICTION is the first-in-human trial of γ9δ2 T-cell antitumor response in solid and hematological tumors with the ICT01 drug

Gamma9 Delta2 (γ9δ2) T cells function at the crossroads of innate and adaptive immunity, with important roles in immune responses against pathogens and carcinogenesis, making them an attractive […]
April 22, 2021

Sintilimab is superior to docetaxel as a second-line treatment for advanced/metastatic SCC of the lung

Patients with advanced lung squamous cell carcinoma (SCC) have very limited second-line treatment options after platinum doublet treatment failure   ORIENT-3 (NCT03150875), a phase III, randomized, open-label and multicenter trial was presented in […]
April 22, 2021

Combination copanlisib plus rituximab demonstrates broad efficacy and superiority versus placebo plus rituximab in patients with relapsed iLNH

Rituximab-based therapies are standard in the treatment of relapsed or refractory indolent non-Hodgkin lymphoma (iLNH). Copanlisib, an intravenous PI3K inhibitor, has demonstrated efficacy and safety as monotherapy […]